丙型肝炎筛查的经济学分析及策略

任天棋; 李腊梅; 杨倩倩; 张霞; 罗利婷; 牛俊奇

doi:10.3969/j.issn.1001-5256.2020.10.032

丙型肝炎筛查的经济学分析及策略

DOI: 10.3969/j.issn.1001-5256.2020.10.032

吉林大学白求恩第一医院肝胆胰内科

详细信息

中图分类号: R512.63
计量
- 文章访问数: 601
- HTML全文浏览量: 60
- PDF下载量: 114
- 被引次数: 0
出版历程
- 收稿日期: 2020-03-29
- 出版日期: 2020-10-20

Advances in economic analysis and screening strategies for hepatitis C screening

Department of Hepatology,The First Hospital of Jilin University

摘要

摘要: 随着直接抗病毒药物的出现,丙型肝炎的抗病毒治疗取得突破性进展,丙型肝炎患者可以实现彻底治愈。由于丙型肝炎起病隐匿,大多数患者并不知道自己的病情,因此,通过筛查来扩大诊治人群是消除丙型肝炎的关键。但HCV感染者在全球范围内分布广、分布不均,导致丙型肝炎筛查、诊治难度大。介绍了目前关于丙型肝炎筛查的经济学研究,分析影响丙型肝炎筛查成本效益的因素,分享其他国家的丙型肝炎消除策略及进展,为我国消除丙型肝炎提供参考。
- 丙型肝炎 /
- 成本及成本分析 /
- 筛查 /
- 早期诊断
Abstract: With the appearance of direct-acting antivirals( DAAs),breakthroughs have been achieved in the antiviral therapy for hepatitis C and hepatitis C patients can be cured completely. Due to the insidious onset of hepatitis C,most patients do not know their own conditions,and thus expanding diagnosis and treatment through screening is the key to the elimination of hepatitis C. However,hepatitis C virus is distributed widely and unevenly in the world,which results in difficulties in the screening and diagnosis of hepatitis C. This article introduces the current economic research on hepatitis C screening,analyzes the factors affecting the cost-effectiveness of hepatitis C screening,and shares the strategies and advances for hepatitis C elimination in other countries,so as to provide a reference for eliminating hepatitis C in China.
- hepatitis C /
- costs and cost analysis /
- screening /
- early diagnosis

HTML全文

参考文献(42)

[1] WHO. Global health sector strategy on viral hepatitis 2016-2021[M/OL]. Geneva:World Health Organization,2016. https://www. Who. int/hepatitis/strategy 2016-2021/ghsshep/en/．

[2] Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. Guidelines for the prevention and treatment of hepatitis C(2019 Version)[J].J Clin Hepatol,2019,35(12):2670-2686.(in Chinese)中华医学会肝病学分会，中华医学会感染病学分会．丙型肝炎防治指南(2019年版)[J]．临床肝胆病杂志，2019,35(12):2670-2686.

[3] ALTHABE F,CHOMBA E,TSHEFU AK,et al. A multifaceted intervention to improve syphilis screening and treatment in pregnant women in Kinshasa,Democratic Republic of the Congo and in Lusaka,Zambia:A cluster randomised controlled trial[J]. Lancet Glob Health,2019,7(5):e655-e663.

[4] COWARD S,LEGGETT L,KAPLAN GG,et al. Cost-effectiveness of screening for hepatitis C virus:A systematic review of economic evaluations[J]. BMJ Open, 2016, 6(9):e011821.

[5] Prevalence of HIV and HCV infection in penitentiary institutions[EB/OL]. http://www. institucionpenitenciaria. es/web/export/sites/default/datos/descargables/saludpublica/Prevalencia(2015).

[6] LLERENA S,COBO C,ALVAREZ S,et al. A program of testing and treat intended to eliminate hepatitis C in a prison:The JAILFREE-C study[J]. Hepatology,2016,64:460A.

[7] DALGIC OO,SAMUR S,SPAULDING AC,et al. Improved health outcomes from hepatitis C treatment scale-up in Spain’s prisons:A cost-effectiveness study[J]. Sci Rep,2019,9(1):16849.

[8] TASILLO A,EFTEKHARI YAZDI G,NOLEN S,et al. Shortterm effects and long-term cost-effectiveness of universal hepatitis C testing in prenatal care[J]. Obstet Gynecol,2019,133(2):289-300.

[9] ASSOUMOU SA,TASILLO A,LEFF JA,et al. Cost-effectiveness of one-time hepatitis C screening strategies among adolescents and young adults in primary care settings[J]. Clin Infect Dis,2018,66(3):376-384.

[10] HILL A,ANDREW B,MELISSA G,et al. Generic treatments for HIV,HBV,HCV,TB could be mass produced for <90per patient[J]. J Int Aids Soc,2017,20:44-45.

[11] HEATH K. Cost-effectiveness analysis of treatment timing considering the future entry of lower-cost generics for hepatitis C[J]. Clinicoecon Outcomes Res,2018,10:539-550.

[12] CHAILLON A,MEHTA SR,HOENIGL M,et al. Cost-effectiveness and budgetary impact of HCV treatment with directacting antivirals in India including the risk of reinfection[J].PLo S One,2019,14(6):e0217964.

[13] CIPRIANO LE,GOLDHABER-FIEBERT JD. Population health and cost-effectiveness implications of a “Treat All”recommendation for HCV:A review of the model-based evidence[J]. MDM Policy Pract,2018,3(1):2381468318776634.

[14] KRAUTH C,ROSSOL S,ORTSTER G,et al. Elimination of hepatitis C virus in Germany:Modelling the cost-effectiveness of HCV screening strategies[J]. BMC Infect Dis,2019,19(1):1019.

[15] WHO. Guidelines on hepatitis B and C testing[M]. Geneva:World Health Organization,2017.

[16] HILL AM,NATH S,SIMMONS B. The road to elimination of hepatitis C:Analysis of cures versus new infections in 91countries[J]. J Virus Erad,2017,3(3):117-123.

[17] RINGELHAN M,MCKEATING JA,PROTZER U. Viral hepatitis and liver cancer[J]. Philos Trans R Soc Lond B Biol Sci,2017,372(1732):20160274.

[18] SMITH BD,MORGAN RL,BECKETT GA,et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965[J]. MMWR Recomm Rep,2012,61(RR-4):1-32.

[19] SMITH BD,MORGAN RL,BECKETT GA,et al. Hepatitis C virus testing of persons born during 1945-1965:Recommendations from the centers for disease control and prevention[J].Ann Intern Med,2012,157(11):817-822.

[20] WARD JW. The epidemiology of chronic hepatitis C and onetime hepatitis C virus testing of persons born during 1945 to 1965in the United States[J]. Clin Liver Dis,2013,17(1):1-11.

[21] MANJELIEVSKAIA J,BROWN D,SHRIVER CD,et al. CDC screening recommendation for baby boomers and hepatitis C virus testing in the US military health system[J]. Public Health Rep,2017,132(5):579-584.

[22] WARD JW. The hidden epidemic of hepatitis C virus infection in the United States:Occult transmission and burden of disease[J]. Top Antivir Med,2013,21(1):15-19.

[23] GREBELY J,BILODEAU M,FELD JJ,et al. The second Canadian symposium on hepatitis C virus:A call to action[J].Can J Gastroenterol,2013,27(11):627-632.

[24] GRAD R,THOMBS BD,TONELLI M,et al. Recommendations on hepatitis C screening for adults[J]. CMAJ,2017,189(16):e594-e604.

[25] TRUBNIKOV M,YAN P,NJIHIA J,et al. Identifying and describing a cohort effect in the national database of reported cases of hepatitis C virus infection in Canada(1991-2010):An age-period-cohort analysis[J]. Cmaj Open,2014,2(4):e281-e287.

[26] GOMAA A,ALLAM N,ELSHARKAWY A,et al. Hepatitis C infection in Egypt:Prevalence,impact and management strategies[J]. Hepat Med,2017,9:17-25.

[27] RICHMOND JA,WALLACE J. Implementation of hepatitis C cure in Australia:One year on[J]. J Virus Erad,2018,4(2):115-117.

[28] China National Narcotics Control Committee. Release of 2018China Drug Situation Report:Overall better but still complex situation in drug control[J]. Shanghai Chem Industry,2019,44(7):45.(in Chinese)国家禁毒委员会．2018年中国毒品形势报告发布:禁毒态势总体趋好、面临形势依然复杂[J]．上海化工，2019,44(7):45.

[29] ZHUANG H. Hepatitis C infection in China:Current status and measures for prevention and treatment[M]. Beijing:People’s Medical Publishing House,2017.(in Chinese)庄辉．中国丙型肝炎感染现状及防治对策研究报告[M]．北京:人民卫生出版社，2017.

[30] TAO LP,FU ZQ,LI ML,et al. Hepatitis C virus infection and related influencing factors in a drug rehabilitation center in Jiangsu Province,China[J]. Acta Univ Med Nanjing(Natural Sci),2019,39(10):1464-1467,1493.(in Chinese)陶礼平，符祖强，李茂林，等．江苏省某戒毒所丙型肝炎病毒感染情况及影响因素分析[J]．南京医科大学学报(自然科学版)，2019,39(10):1464-1467,1493.

[31] CONG Y,WANG XG,YE L,et al. Analysis of sexually transmitted diseases infection and its influencing factors among isolated drug users in Zhejiang Province[J]. Chin J Health Lab Tec,2020,30(2):252-254,257.(in Chinese)丛迎，王晓光，叶灵，等．浙江省强制隔离戒毒人群性传播疾病感染状况及影响因素分析[J]．中国卫生检验杂志，2020,30(2):252-254,257.

[32] HU AY,DENG JH,DONG XY,et al. HIV and HCV infection status and influence factors among drug addicts under compulsory rehabilitation in Baoshan city of Yunnan province[J].Chin J AIDS STD,2019,25(11):1113-1116.(in Chinese)胡安艳，邓家欢，董贤雅，等．保山市强制戒毒人员HIV和HCV感染状况及影响因素[J]．中国艾滋病性病，2019,25(11):1113-1116.

[33] van de VEN N,FORTUNAK J,SIMMONS B,et al. Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus[J]. Hepatology,2015,61(4):1174-1182.

[34] National Health and Family Planning Commission of the People’s Republic of China. Screening and management of viral hepatitis C[J]. Infect Dis Info,2015,1:1-2.(in Chinese)中华人民共和国国家卫生和计划生育委员会．丙型病毒性肝炎筛查及管理[J]．传染病信息，2015,1:1-2.

[35] CUI MJ. A case-control study of risk factors for HCV infection[D]. Beijing:Chinese Center for Disease Control and Prevention,2014.(in Chinese)崔妹娟．HCV感染危险因素的病例对照研究[D]．北京:中国疾病预防控制中心，2014.

[36] National Health and Family Planning Commission,National Development and Reform Commission, Ministry of Education,et al. Action plan for the prevention and treatment of viral hepatitis in China(2017-2020)[J]. Chin J Viral Dis,2018,8(1):1-5.(in Chinese)国家卫生计生委，国家发展改革委，教育部，等．中国病毒性肝炎防治规划(2017-2020年)[J]．中国病毒病杂志，2018,8(1):1-5.

[37] LIU L,XU H,HU Y,et al. Hepatitis C screening in hospitals:Find the missing patients[J]. Virol J,2019,16(1):47.

[38] LI R. Construction plan for national production bases of genuine medicinal materials(2018-2025)jointly issued by Ministry of Agriculture and Rural Affairs,National Medical Products Administration,and State Administration of Traditional Chinese Medicine[J]. J Tradit Chin Med Manage,2018,26(24):inside back cover.(in Chinese)李芮．三部委联合印发《全国道地药材生产基地建设规划(2018-2025年)》[J]．中医药管理杂志，2018,26(24):封3.

[39] Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015:A modelling study[J]. Lancet Gastroenterol Hepatol,2017,2(3):161-176.

[40] TANG Y,SUN Q,GU CH,et al. Sentinel surveillance of HIV,hepatitis C and syphilis infections[J]. J Diagn Concepts Pract,2013,12(3):352-354.(in Chinese)汤琰，孙乔，顾春华，等．哨点监测人群中人类免疫缺陷病毒、梅毒、HCV感染的检测结果分析[J]．诊断学理论与实践，2013,12(3):352-354.

[41] Chinese Center for Disease Control and Prevention. Ministry of Health issued the epidemic situation of notifiable infectious diseases in 2008 and January 2009 in China[R/OL].[2009-02-10]http://www. nhc. gov. cn/jkj/s3578/201304/c9244b1ae3ad48faa8181b87b8caffd5. shtml.(in Chinese)中国疾病预防控制中心．卫生部公布2009年1月及2008年度全国法定报告传染病疫情[R/OL].[2009-02-10] http://www. nhc. gov. cn/jkj/s3578/201304/c9244b1ae3ad48faa8181b87b8caffd5. shtml.

[42] Chinese Center for Disease Control and Prevention. An overview of the epidemic situation of notifiable infectious diseases in China,2018[R/OL].[2019-04-24] http://www. nhc.gov. cn/jkj/s3578/201904/050427ff32704a5db64f4ae1f6d57c6c.shtml.(in Chinese)中国疾病预防控制中心．2018年全国法定传染病疫情概况[R/OL].[2019-04-24]. http://www. nhc. gov. cn/jkj/s3578/201904/050427ff32704a5db64f4ae1f6d57c6c. shtml.

施引文献

资源附件(0)

访问统计